Published in Oncotarget on April 30, 2014
Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway. Oncotarget (2016) 0.83
The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications. Oncotarget (2015) 0.80
ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression. Oncotarget (2016) 0.79
Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers. Dis Model Mech (2016) 0.77
DDA1 promotes stage IIB-IIC colon cancer progression by activating NFκB/CSN2/GSK-3β signaling. Oncotarget (2016) 0.76
A new layer of degradation mechanism for PR-Set7/Set8 during cell cycle. Cell Cycle (2016) 0.75
Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness. Sci Rep (2015) 0.75
Cancer stem cells and early stage basal-like breast cancer. World J Obstet Gynecol (2016) 0.75
Estrogenic regulation of skeletal muscle proteome: a study of premenopausal women and postmenopausal MZ cotwins discordant for hormonal therapy. Aging Cell (2017) 0.75
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis (1999) 45.01
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Universal sample preparation method for proteome analysis. Nat Methods (2009) 16.88
qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol (2007) 16.15
Triple-negative breast cancer. N Engl J Med (2010) 11.39
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol Cell (2009) 2.79
CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem (2008) 2.63
SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J (2003) 2.16
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology (2002) 2.05
Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med (2011) 2.03
Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res (2003) 1.94
The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res (1998) 1.88
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res (2012) 1.78
Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A (2009) 1.66
Functional cooperation between FACT and MCM helicase facilitates initiation of chromatin DNA replication. EMBO J (2006) 1.60
CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res (2013) 1.48
Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene (2010) 1.46
Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res (2004) 1.40
The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. EMBO J (2010) 1.36
Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res (2009) 1.32
Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene (2007) 1.28
Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res (2007) 1.27
HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One (2013) 1.25
Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res (2007) 1.22
Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med (2011) 1.21
High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol (2011) 1.16
Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia (2009) 1.14
Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med (Berl) (2012) 1.12
Pathogenic Role of the CRL4 Ubiquitin Ligase in Human Disease. Front Oncol (2012) 1.08
Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol (2011) 1.03
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res (2012) 1.01
Inhibition of tumor cell motility by the interferon-inducible GTPase MxA. J Biol Chem (2009) 0.97
Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One (2012) 0.96
MYC addiction: a potential therapeutic target in MM. Blood (2012) 0.96
Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med (2012) 0.94
The CUL4 enigma: culling DNA repair factors. Mol Cell (2009) 0.93
Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother (2011) 0.89
Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice. Cancer Prev Res (Phila) (2012) 0.88
Smurf1 protein negatively regulates interferon-γ signaling through promoting STAT1 protein ubiquitination and degradation. J Biol Chem (2012) 0.87
The phosphorylation of SEPT2 on Ser218 by casein kinase 2 is important to hepatoma carcinoma cell proliferation. Mol Cell Biochem (2009) 0.84
Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice. Biochem Biophys Res Commun (2013) 0.84
Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response. Mol Cancer Ther (2013) 0.80
Breast cancer: HER2--a good addiction. Nat Rev Clin Oncol (2012) 0.78
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
A micrococcal nuclease homologue in RNAi effector complexes. Nature (2003) 3.67
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell (2009) 3.03
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev (2011) 2.63
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell (2012) 2.18
Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet (2013) 2.15
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat (2006) 2.10
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Genetic polymorphisms among C57BL/6 mouse inbred strains. Transgenic Res (2010) 1.81
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat (2008) 1.72
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res (2011) 1.58
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother (2011) 1.56
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat (2003) 1.54
Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet (2011) 1.51
Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Res (2010) 1.51
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat (2005) 1.45
Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancer. Ann Surg Oncol (2003) 1.45
Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer (2002) 1.44
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res (2008) 1.43
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res (2003) 1.39
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Polycomb subunits Ezh1 and Ezh2 regulate the Merkel cell differentiation program in skin stem cells. EMBO J (2013) 1.33
Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res (2009) 1.32
ERCC4 associated with breast cancer risk: a two-stage case-control study using high-throughput genotyping. Cancer Res (2006) 1.29
Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol (2006) 1.27
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer (2004) 1.24
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.23
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol (2006) 1.20
IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks. J Clin Microbiol (2004) 1.20
Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood (2011) 1.18
The (1,3)beta-D-glucan synthase subunit Bgs1p is responsible for the fission yeast primary septum formation. Mol Microbiol (2007) 1.18
Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst (2010) 1.17
Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Hum Mol Genet (2011) 1.16
Autofluorescence of mycobacteria as a tool for detection of Mycobacterium tuberculosis. J Clin Microbiol (2008) 1.16
A proteomic characterization of factors enriched at nascent DNA molecules. Cell Rep (2013) 1.15
The complex genetic landscape of familial breast cancer. Hum Genet (2013) 1.14
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol (2005) 1.14
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One (2012) 1.13
Evaluating HapMap SNP data transferability in a large-scale genotyping project involving 175 cancer-associated genes. Hum Genet (2005) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother (2009) 1.12
Failure to implement evidence-based clinical guidelines for sepsis at the ED. Am J Emerg Med (2006) 1.12
A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet (2011) 1.10
Mycobacterium canariasense sp. nov. Int J Syst Evol Microbiol (2004) 1.10
The Mycobacterium tuberculosis phoPR operon is positively autoregulated in the virulent strain H37Rv. J Bacteriol (2008) 1.08
Portal hyperperfusion: mechanism of injury and stimulus for regeneration in porcine small-for-size transplantation. Liver Transpl (2010) 1.07
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol (2005) 1.05
Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res (2003) 1.04
Modification and activation of Ras proteins by electrophilic prostanoids with different structure are site-selective. Biochemistry (2007) 1.04
Fission yeast Ags1 confers the essential septum strength needed for safe gradual cell abscission. J Cell Biol (2012) 1.03
Methylthioadenosine reverses brain autoimmune disease. Ann Neurol (2006) 1.03
Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. Clin Chem (2006) 1.03
Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res Treat (2011) 1.03
Pigmentation-related genes and their implication in malignant melanoma susceptibility. Exp Dermatol (2009) 1.02
Over-representation of two specific haplotypes among chromosomes harbouring BRCA1 mutations. Eur J Hum Genet (2003) 1.02
RNA interference: a promising approach to antiviral therapy? Trends Mol Med (2002) 1.02
Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma. Cancer Res (2007) 1.01
An in vivo RNAi screening approach to identify host determinants of virus replication. Cell Host Microbe (2013) 1.01
An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Carcinogenesis (2008) 1.01
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet (2013) 1.00
Superior preservation of DCD livers with continuous normothermic perfusion. Ann Surg (2011) 0.99
Genome-wide linkage scan reveals three putative breast-cancer-susceptibility loci. Am J Hum Genet (2009) 0.99
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res (2014) 0.99
Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol (2007) 0.98
The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes Dev (2014) 0.98
Identification and functional analysis of novel variants of the human melanocortin 1 receptor found in melanoma patients. Hum Mutat (2009) 0.97
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2009) 0.97
Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array. Genes Chromosomes Cancer (2005) 0.96
Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility. Breast Cancer Res Treat (2008) 0.96
9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2012) 0.95
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer (2002) 0.95
Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer (2002) 0.95
Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin Cancer Res (2007) 0.95
p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res (2002) 0.95
RockerBox: analysis and filtering of massive proteomics search results. J Proteome Res (2011) 0.95
Latest findings about the interplay of auxin, ethylene and nitric oxide in the regulation of Fe deficiency responses by Strategy I plants. Plant Signal Behav (2011) 0.95
Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. Hum Mutat (2007) 0.95
Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One (2011) 0.94
Mortality-related factors after hospitalization for acute exacerbation of chronic obstructive pulmonary disease: the burden of clinical features. Am J Emerg Med (2007) 0.94
aPKC phosphorylates NuMA-related LIN-5 to position the mitotic spindle during asymmetric division. Nat Cell Biol (2011) 0.93